Pharmaceutical company Lek, a subsidiary of Novartis's generic arm Sandoz, posted sales of EUR 721m for 2006, an increase of 33% over the year before. Lek said profits grew significantly, but it did not disclose the figures in Friday's press release.
Prescription drugs accounted for the bulk of revenues (EUR 573m), with over-the-counter drugs adding EUR 80m, pharmaceutical ingredients EUR 46m and other products EUR 22m.
The company's main market is Central and Eastern Europe, which accounts for 28% of the sales, followed by the US and overseas markets (43%) and Slovenia (9%).
Sales expanded briskly in all markets bar Slovenia, where Lek says prices have been dropping.
The company earmarked EUR 68.3m for development last year, or 9.5% of total sales.
At the end of September construction started on a new biopharmacy centre, which Lek says will cement its leading position in biopharmacy in the Sandoz group.
The facility, which is estimated at EUR 6.7m, is being built at Lek headquarters in Ljubljana and is expected to open in the autumn.
Lek's parent company, the Swiss pharma giant Novartis, posted a net profit of US$ 7.2bn on sales of US$ 37bn.
More articles from this issue:
Archive
|